ClinicalTrials.gg
CompletedNCT05478252Updated Dec 12, 2025Results posted

A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes

A Phase 3 interventional study of Semaglutide J and Semaglutide B in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 104 sites in 5 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
388
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
47th of 163
388 · median 104
Started
2022
with 17 others
Phase 3
57 of 163
7 open now
Registered
102nd of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 47th largest by enrollment, is one of 18 that started in 2022, is one of 57 in phase 3, and was the 102nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D). Participants will either get the currently available semaglutide or the semaglutide which is produced through a new manufacturing process. Participants need to take one injection of semaglutide once a week, on the same day of every week. Participants will have a total of 11 clinic visits and the study will last for about 35 weeks (approximately 8 months).

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with type 2 diabetes (T2D) mellitus greater than equal to (≥) 180 days before screening.
  • Stable daily dose(s) ≥ 90 days prior to the day of screening of metformin ≥ 1500 milligrams (mg) or maximum tolerated or effective dose.
  • of 7.0-10.5 percentage (%) [53-91.3 millimoles per mole (mmol/mol)] (both inclusive).

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 days and prior insulin treatment for gestational diabetes are allowed.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for nondilated examination.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
388 participants (actual)

Study arms

  • Experimental
    Semaglutide J

    Participants will initially receive 0.25 milligrams (mg) subcutaneous injections of semaglutide J once weekly (OW) and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks. Metformin will be considered as background therapy during the trial.

    Drug: Semaglutide J

  • Active comparator
    Semaglutide B

    Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks. Metformin will be considered as background therapy during the trial.

    Drug: Semaglutide B

Interventions

  • Participants will initially receive 0.25 mg subcutaneous injections of semaglutide J OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).

  • Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).

06

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Change in HbA1c from baseline (week 0) to end of treatment (week 28) is presented. The endpoint was evaluated based on the data from in-study period. The in-study period is defined as the uninterrupted time interval from date of randomisation to date of least contact with trial site.

    Time frame: From baseline (week 0) to end of treatment (week 28)

Secondary outcomes

  1. Change in Body Weight

    Change in body weight from baseline (week 0) to end of treatment (week 28) is presented. The endpoint was evaluated based on the data from in-study period. The in-study period is defined as the uninterrupted time interval from date of randomisation to date of least contact with trial site.

    Time frame: From baseline (week 0) to end of treatment (week 28)

  2. Number of Treatment-Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an IMP. All presented adverse events are TEAE. A TEAE is defined as an adverse event with an onset date (or increase in severity) during the on-treatment observation period. On-treatment observation period is defined as from first drug date until the end of study.

    Time frame: From the time of first dosing (week 0) to end of study (week 33)

  3. Occurrence of Anti-semaglutide Antibodies (Yes/no)

    Occurrence of anti-semaglutide antibodies for in-study observation period is presented. The in-study period is defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. In the reported data 'yes' infers who tested positive for anti-semaglutide antibodies, whereas 'No' infers who tested negative for anti semaglutide antibodies.

    Time frame: From baseline (week 0) to end of study (week 33)

  4. Occurrence of Anti-semaglutide Antibodies With In-vitro Neutralising Effect (Yes/no)

    Occurrence of anti-semaglutide antibodies with in-vitro neutralizing effect was to be performed based on positive cross -reactivity to GLP-1. Since there was no sample with positive cross -reactivity to GLP-1, no further analysis was performed for invitro neutralizing effect towards native-GLP1. Therefore, no data is available for this end point. In the reported data 'yes' infers who tested positive for anti-semaglutide antibodies whereas 'No' infers who tested negative for anti-semaglutide antibodies.

    Time frame: From baseline (week 0) to end of study (week 33)

  5. Occurrence of Anti-semaglutide Binding Antibodies Cross-reacting With Endogenous Glucagon Like Peptide-1 (GLP-1) (Yes/no)

    Occurrence of anti-semaglutide binding antibodies cross-reacting with endogenous glucagon like peptide-1 (GLP-1) for in-study observation period is presented. The in-study period is defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. In the reported data 'yes' infers who tested positive for anti-semaglutide binding antibodies cross-reacting with endogenous glucagon like peptide-1 (GLP-1) whereas 'No' infers who tested negative for anti-semaglutide binding antibodies cross-reacting with endogenous glucagon like peptide-1 (GLP-1).

    Time frame: From baseline (week 0) to end of study (week 33)

  6. Occurrence of In-vitro Neutralising Cross-reacting Antibodies to Endogenous GLP-1 (Yes/no)

    Occurrence of in-vitro neutralising cross-reacting antibodies to endogenous GLP-1 at week 33 is presented. In the reported data 'yes' infers who tested positive for in-vitro neutralising cross-reacting antibodies to endogenous GLP-1 whereas 'No' infers who tested negative for in-vitro neutralising cross-reacting antibodies to endogenous GLP-1.

    Time frame: At week 33

  7. Anti-semaglutide Antibodies Level Measured as Percentage (%) Bound/Total

    Anti-semaglutide antibodies level measured as %Bound/Total at week 33 is presented.

    Time frame: At week 33

  8. Anti-semaglutide Antibodies Level (Measured as Titre)

    Anti-semaglutide antibodies level measured as titre at week 33 is presented.

    Time frame: At week 33

07

Results

Posted Oct 9, 2024

Participant flow

The trial was conducted at 73 sites in Slovakia, Poland, South Africa, the United States and Canada.

Participant flow — Overall Study
MilestoneSemaglutide JSemaglutide B
Started29197
Full analysis set29197
Safety analysis set29197
Completed28391
Not completed86
Withdrew: Withdrawal by subject23
Withdrew: Lost to follow-up42
Withdrew: Physician decision11
Withdrew: Death10

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c)

Change in HbA1c from baseline (week 0) to end of treatment (week 28) is presented. The endpoint was evaluated based on the data from in-study period. The in-study period is defined as the uninterrupted time interval from date of randomisation to date of least contact with trial site.

Time frame:
From baseline (week 0) to end of treatment (week 28)
Reported as:
Mean · Percentage of glycosylated haemoglobin
Change in Glycosylated Haemoglobin (HbA1c)
Percentage of glycosylated haemoglobinSemaglutide JSemaglutide B
Change in Glycosylated Haemoglobin (HbA1c)-1.7 ± 1.0-1.6 ± 1.0
Statistical analysis
  • Semaglutide J vs Semaglutide B · ANCOVA · p = <.0001 · Treatment difference: -0.11 · 95% CI -0.30 to 0.08
SecondaryChange in Body Weight

Change in body weight from baseline (week 0) to end of treatment (week 28) is presented. The endpoint was evaluated based on the data from in-study period. The in-study period is defined as the uninterrupted time interval from date of randomisation to date of least contact with trial site.

Time frame:
From baseline (week 0) to end of treatment (week 28)
Reported as:
Mean · Kilogram (kg)
Change in Body Weight
Kilogram (kg)Semaglutide JSemaglutide B
Change in Body Weight-5.0 ± 5.0-4.6 ± 4.4
SecondaryNumber of Treatment-Emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of an IMP. All presented adverse events are TEAE. A TEAE is defined as an adverse event with an onset date (or increase in severity) during the on-treatment observation period. On-treatment observation period is defined as from first drug date until the end of study.

Time frame:
From the time of first dosing (week 0) to end of study (week 33)
Reported as:
Number · Events
Number of Treatment-Emergent Adverse Events (TEAEs)
EventsSemaglutide JSemaglutide B
Number of Treatment-Emergent Adverse Events (TEAEs)15652
SecondaryOccurrence of Anti-semaglutide Antibodies (Yes/no)

Occurrence of anti-semaglutide antibodies for in-study observation period is presented. The in-study period is defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. In the reported data 'yes' infers who tested positive for anti-semaglutide antibodies, whereas 'No' infers who tested negative for anti semaglutide antibodies.

Time frame:
From baseline (week 0) to end of study (week 33)
Reported as:
Count of participants · Participants
Occurrence of Anti-semaglutide Antibodies (Yes/no)
ParticipantsSemaglutide JSemaglutide B
Yes10
No28190
SecondaryOccurrence of Anti-semaglutide Antibodies With In-vitro Neutralising Effect (Yes/no)

Occurrence of anti-semaglutide antibodies with in-vitro neutralizing effect was to be performed based on positive cross -reactivity to GLP-1. Since there was no sample with positive cross -reactivity to GLP-1, no further analysis was performed for invitro neutralizing effect towards native-GLP1. Therefore, no data is available for this end point. In the reported data 'yes' infers who tested positive for anti-semaglutide antibodies whereas 'No' infers who tested negative for anti-semaglutide antibodies.

Time frame:
From baseline (week 0) to end of study (week 33)

No measurements were reported for this outcome.

SecondaryOccurrence of Anti-semaglutide Binding Antibodies Cross-reacting With Endogenous Glucagon Like Peptide-1 (GLP-1) (Yes/no)

Occurrence of anti-semaglutide binding antibodies cross-reacting with endogenous glucagon like peptide-1 (GLP-1) for in-study observation period is presented. The in-study period is defined as the uninterrupted time interval from date of randomisation to date of last contact with trial site. In the reported data 'yes' infers who tested positive for anti-semaglutide binding antibodies cross-reacting with endogenous glucagon like peptide-1 (GLP-1) whereas 'No' infers who tested negative for anti-semaglutide binding antibodies cross-reacting with endogenous glucagon like peptide-1 (GLP-1).

Time frame:
From baseline (week 0) to end of study (week 33)
Reported as:
Count of participants · Participants
Occurrence of Anti-semaglutide Binding Antibodies Cross-reacting With Endogenous Glucagon Like Peptide-1 (GLP-1) (Yes/no)
ParticipantsSemaglutide JSemaglutide B
Yes00
No10
SecondaryOccurrence of In-vitro Neutralising Cross-reacting Antibodies to Endogenous GLP-1 (Yes/no)

Occurrence of in-vitro neutralising cross-reacting antibodies to endogenous GLP-1 at week 33 is presented. In the reported data 'yes' infers who tested positive for in-vitro neutralising cross-reacting antibodies to endogenous GLP-1 whereas 'No' infers who tested negative for in-vitro neutralising cross-reacting antibodies to endogenous GLP-1.

Time frame:
At week 33
Reported as:
Count of participants · Participants
Occurrence of In-vitro Neutralising Cross-reacting Antibodies to Endogenous GLP-1 (Yes/no)
ParticipantsSemaglutide JSemaglutide B
Yes00
No10
SecondaryAnti-semaglutide Antibodies Level Measured as Percentage (%) Bound/Total

Anti-semaglutide antibodies level measured as %Bound/Total at week 33 is presented.

Time frame:
At week 33
Reported as:
Mean · Percentage of Antisemaglutide Antibodies
Anti-semaglutide Antibodies Level Measured as Percentage (%) Bound/Total
Percentage of Antisemaglutide AntibodiesSemaglutide JSemaglutide B
Anti-semaglutide Antibodies Level Measured as Percentage (%) Bound/Total3.47 ± 0.00—
SecondaryAnti-semaglutide Antibodies Level (Measured as Titre)

Anti-semaglutide antibodies level measured as titre at week 33 is presented.

Time frame:
At week 33
Reported as:
Mean · Titre
Anti-semaglutide Antibodies Level (Measured as Titre)
TitreSemaglutide JSemaglutide B
Anti-semaglutide Antibodies Level (Measured as Titre)15.00 ± 0.00—

Adverse events

Collected over From the time of first dosing (week 0) to end of study (week 33). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Semaglutide J1/291 (0.3%)8/291 (2.7%)64/291 (22%)
Semaglutide B0/97 (0%)5/97 (5.2%)24/97 (24.7%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventSemaglutide JSemaglutide B
Atrial fibrillationCardiac disorders0/2911/97
HaematuriaRenal and urinary disorders0/2911/97
NephrolithiasisRenal and urinary disorders0/2911/97
PancreatitisGastrointestinal disorders0/2911/97
Umbilical herniaGastrointestinal disorders0/2911/97
Acute myocardial infarctionCardiac disorders1/2910/97
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/2910/97
Benign salivary gland neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2910/97
Cardiac failure acuteCardiac disorders1/2910/97
Cardiopulmonary failureCardiac disorders1/2910/97
Most frequent other events
Most frequent other events
EventSemaglutide JSemaglutide B
NauseaGastrointestinal disorders35/29115/97
DiarrhoeaGastrointestinal disorders26/2917/97
HeadacheNervous system disorders17/2912/97
VomitingGastrointestinal disorders15/2915/97

Baseline characteristics

Full analysis set (FAS) included all randomized participants

Age, Continuous
Age, Continuous(Years)Semaglutide JSemaglutide BTotal
Mean53.7 ± 7.754.8 ± 7.154.0 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Semaglutide JSemaglutide BTotal
Female12847175
Male16350213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Semaglutide JSemaglutide BTotal
Hispanic or Latino562581
Not Hispanic or Latino23572307
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Semaglutide JSemaglutide BTotal
American Indian or Alaska Native000
Asian271239
Native Hawaiian or Other Pacific Islander011
Black or African American481260
White21472286
More than one race202
Unknown or Not Reported000
08

Study locations

104 sites
  • Prime Medical Group, LLC
    Gilbert, Arizona 85296, United States
  • FDRC
    Costa Mesa, California 92627, United States
  • Velocity Clinical Research San Diego
    La Mesa, California 91942, United States
  • Velocity Clin Res Los Angeles
    Los Angeles, California 90017, United States
  • LCGK Research
    San Carlos, California 94070, United States
  • San Diego Family Care_San Diego
    San Diego, California 92111, United States
  • Encompass Clinical Research_Spring Valley
    Spring Valley, California 91978, United States
  • Med Partners, Inc.
    Toluca Lake, California 91602, United States
  • University Clin Investigators
    Tustin, California 92780, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Innovative Research of W Florida Inc.
    Clearwater, Florida 33756, United States
  • Innovative Research of W FL
    Clearwater, Florida 33756, United States
  • Alliance for Multispec Res
    Coral Gables, Florida 33134, United States
  • Encore Medical Research LLC
    Hollywood, Florida 33024, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Reyes Clinical Research, Inc
    Miami, Florida 33175, United States
  • International Research Associates, LLC_Miami
    Miami, Florida 33183, United States
  • South Broward Research LLC
    Miramar, Florida 33027, United States
  • Adult Medicine of Lake County, Inc.
    Mt. Dora, Florida 32757, United States
  • Omega Research Consultants LLC
    Orlando, Florida 32806, United States
  • South Broward Research LLC
    Pembroke Pines, Florida 33027, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • CVS Store Number: 7689
    Atlanta, Georgia 30329-4015, United States
  • CVS Store Number: 05520
    Savannah, Georgia 31405-6901, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Macoupin Research Group
    Gillespie, Illinois 62033, United States
  • Clin Invest Spec, Inc
    Wauconda, Illinois 60084, United States
  • The Research Group of Lexington LLC
    Lexington, Kentucky 40503, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • BTC of New Bedford, LLC
    New Bedford, Massachusetts 02740, United States
  • Elite Research Center
    Flint, Michigan 48532, United States
  • Arcturus Healthcare, PLC.
    Troy, Michigan 48098, United States
  • Montana Medical Research
    Missoula, Montana 59808, United States
  • N.Y. Family Practice Physicians
    Woodhaven, New York 11421, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Whiteville Medical Assoc, PA
    Whiteville, North Carolina 28472, United States
  • Albert J Weisbrot
    Mason, Ohio 45040-6815, United States
  • Advanced Med Res Maumee
    Maumee, Ohio 43537, United States
  • Tristar Clin Investigations, PC
    Philadelphia, Pennsylvania 19114, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • Elligo Clin Res Centre
    Austin, Texas 78704, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • UT Southwestern Med Cntr
    Dallas, Texas 75390-9302, United States
  • Southwest Clinical Trials
    Houston, Texas 77081, United States
  • Tapia Internal Medicine Clinic
    Paris, Texas 75462, United States
  • Univ Of Texas Hlth Science Cntr
    San Antonio, Texas 78229, United States
  • VIP Trials_San Antonio
    San Antonio, Texas 78230, United States
  • VIP Trials
    San Antonio, Texas 78230, United States
  • Dwayne O. Williams, M.D., P.A.
    Sugar Land, Texas 77479, United States
  • Sugar Lakes Family Practice PA
    Sugar Land, Texas 77479, United States
  • Martin Diagnostic Clinic
    Tomball, Texas 77375, United States
  • CVS Store Number: 01396
    Reston, Virginia 20191-4327, United States
  • CVS Store Number: 1537
    Richmond, Virginia 23230-3005, United States
  • Wenatchee Valley Hospital and Clinics
    Wenatchee, Washington 98801-2028, United States
  • Care Clinic
    Red Deer, Alberta T4P 1K4, Canada
  • Ocean West Research Clinic
    Surrey, British Columbia V3Z 2N6, Canada
  • G.A. Research Associates Ltd.
    Moncton, New Brunswick E1G 1A7, Canada
  • Nova Scotia Hlth Halifax
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Centricity Research New Minas
    New Minas, Nova Scotia B4N 3R7, Canada
  • Centricity Research Brampton
    Brampton, Ontario L6S 0C6, Canada
  • LMC Clin Res Inc. Thornhill
    Concord, Ontario L4K 4M2, Canada
  • Medical Trust Clinics, Inc.
    Courtice, Ontario L1E2J5, Canada
  • Centricity Research Etobicoke
    Etobicoke, Ontario M9R 4E1, Canada
  • Wharton Med Clin Trials
    Hamilton, Ontario L8L 5G8, Canada
  • Milestone Research
    London, Ontario N5W 6A2, Canada
  • Bluewater Clin Res Group,Inc
    Sarnia, Ontario N7T 4X3, Canada
  • Canadian Centre for Research on Diabetes_Smiths Falls
    Smiths Falls, Ontario K7A 4W8, Canada
  • LMC Endo Centres Ltd.(Bayview)
    Toronto, Ontario M4G 3E8, Canada
  • LMC Manna Research
    Toronto, Ontario M4G 3E8, Canada
  • Manna Research Quebec
    Lévis, Quebec G6W 0M5, Canada
  • Recherche GCP Research
    Montreal, Quebec H1Y 3H5, Canada
  • LMC Clin Rsrch Inc. (Montreal)
    Montreal, Quebec H4T 1Z9, Canada
  • Centricity Res Pointe-Claire
    Pointe-Claire, Quebec H9R 4S3, Canada
  • Manna Research Inc.
    Pointe-Claire, Quebec H9R 4S3, Canada
  • Centricity Research Ville St. Laurent VSL
    Saint-Laurent, Quebec H4T 1Z9, Canada
  • Beata Miklaszewicz&Dariusz Dabrowski "CARDIAMED" s.j.
    Legnica, Lower Silesian Voivodeship 59-220, Poland
  • ETG Lublin
    Lublin, Lublin Voivodeship 20-412, Poland
  • Osteo Medic s.c. Artur Racewicz Jerzy Supronik
    Bialystok, 15-351, Poland
  • NZOZ Specjalistyczny Osrodek Internistyczno-Diabetologiczny Małgorzata Arciszewska
    Bialystok, 15-435, Poland
  • M2M Badania Kliniczne
    Chorzów, 41-500, Poland
  • NZOZ Gdanska Poradnia Cukrzycowa Sp.z o.o.
    Gdansk, 80-858, Poland
  • Krakowskie Centrum Medyczne Sp. z o.o.
    Krakow, 31-501, Poland
  • FutureMeds Sp. z o.o. Lodz
    Lodz, 91-363, Poland
  • ETG Lublin
    Lublin, 20-412, Poland
  • Centrum Medyczne "Diabetika"
    Radom, 26-600, Poland
  • PANSTWOWY INSTYTUT MEDYCZNY MSWiA
    Warsaw, 02-507, Poland
  • FutureMeds Sp. z o.o.
    Wroclaw, 50-088, Poland
  • Diabetologicka ambulancia DIASTYLE s.r.o.
    Banská Bystrica, 97401, Slovakia
  • Diabetologicka ambulancia DIAMO s.r.o.
    Kežmarok, 06001, Slovakia
  • IVAMEDIC s.r.o.
    Košice, 040 11, Slovakia
  • DIA - SANTMART, s.r.o., Ambulancia diabetologie a poruch latkovej premeny a vyzivy
    Martin, 036 01, Slovakia
  • Diabetologicka ambulancia MUDr. Iveta Markova s.r.o
    Nitra, 94911, Slovakia
  • MUDr. Jan Culak, s.r.o.
    Prievidza, 97101, Slovakia
  • MEDI-DIA s.r.o.
    Sabinov, 08301, Slovakia
  • Medi-Clinic Bloemfontein
    Bloemfontein, Free State 9301, South Africa
  • Moriana Clinical Research
    Winnie Mandela, Free State 9400, South Africa
  • Shop#1 Health Emporium
    Midrand, Gauteng 1685, South Africa
  • Prinshof Medical Campus
    Pretoria, Gauteng 0002, South Africa
  • Jongaie Research
    Pretoria, Gauteng 0183, South Africa

Showing the first 100 of 104 sites across 5 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Aug 2023, 12 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 12 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2022
First posted
Jul 28, 2022
StartActual
Aug 3, 2022
Primary completionActual
Aug 9, 2023
CompletionActual
Sep 18, 2023
Results first posted
Oct 9, 2024
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05478252
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 28, 2022
Start date
Aug 3, 2022
Primary completion
Aug 9, 2023
Completion
Sep 18, 2023
Results posted
Oct 9, 2024
Last update
Dec 12, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion